Nose-to-Brain Delivery of Biopharmaceutics for the therapy of central nervous system diseases: A design-based approach for efficient drug delivery systems

Project Information

Bio2Brain

Grant agreement ID: 956977

DOI 10.3030/956977

EC signature date 18 August 2020

Start date 1 January 2021

End date 31 December 2024

Funded under

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Total cost € 3 493 709,61

EU contribution € 3 493 709,61

Coordinated by

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
Germany

Deliverables

Websites, patent fillings, videos etc. (6)

Semi-annual Newsletter M10

Semiannual Newsletter M10

Semi-annual Newsletter M27

Semiannual Newsletter M27

Bio2Brain Website
Semi-annual Newsletter M21

Semiannual Newsletter M21

Semi-annual Newsletter M15

Semiannual Newsletter M15

EAN conference

Other (1)

1st Summer School

Publications

Peer reviewed articles (2)

Editorial: Intranasal Drug Delivery: Challenges and Opportunities

Author(s): A. Fortuna, K. Schindowski, F. Sonvico
Published in: Frontiers in Pharmacology, 2022, ISSN 1663-9812
Publisher: Frontiers Media S.A.
DOI: 10.3389/fphar.2022.868986

Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions

Author(s): D. T. Abdeldaim, K. Schindowski
Published in: Pharmaceutics, 2023, ISSN 1999-4923
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics15102402